Galmed Pharmaceuticals (GLMD) Income from Continuing Operations (2013 - 2020)
Galmed Pharmaceuticals (GLMD) recorded quarterly Income from Continuing Operations of 6861000.0 in Q1 2020, down 17.2% quarter-over-quarter from 8286000.0 in Q4 2019, and up 49.54% on a YoY basis from 4588000.0 in Q2 2019.
Galmed Pharmaceuticals (GLMD) Income from Continuing Operations (2013 - 2020) Analysis & Trends
Galmed Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 6861000.0 for Q1 2020.
- In Q1 2020, Income from Continuing Operations rose 49.54% year-over-year to 6861000.0; the TTM figure through Mar 2020 stood at 24249000.0 (up 105.71% YoY), while the FY2024 annual figure was 1707000.0, up 8.45% from the prior year.
- Income from Continuing Operations was 6861000.0 for Q1 2020 at Galmed Pharmaceuticals, down from 8286000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 8286000.0 in Q4 2019 to a low of 809000.0 in Q3 2018.
- Historically, Income from Continuing Operations has averaged 3971437.5 across 5 years, with a median of 3675000.0 in 2017.
- The sharpest annual moves came in 2018 and 2019: Income from Continuing Operations slumped 71.12% in 2018, then surged 457.97% in 2019.
- A 5-year view of Income from Continuing Operations shows it stood at 4826000.0 in 2016, then dropped by 24.49% to 3644000.0 in 2017, then grew by 1.7% to 3706000.0 in 2018, then surged by 123.58% to 8286000.0 in 2019, then retreated by 17.2% to 6861000.0 in 2020.
- The last three Income from Continuing Operations figures came in at 6861000.0 (Q1 2020), 8286000.0 (Q4 2019), and 4514000.0 (Q3 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 6.86 Mn |
| Dec 31, 2019 | 8.29 Mn |
| Sep 30, 2019 | 4.51 Mn |
| Mar 31, 2019 | 4.59 Mn |
| Dec 31, 2018 | 3.71 Mn |
| Sep 30, 2018 | 809,000.00 |
| Jun 30, 2018 | 2.69 Mn |
| Mar 31, 2018 | 2.61 Mn |
| Dec 31, 2017 | 3.64 Mn |
| Sep 30, 2017 | 2.80 Mn |
| Jun 30, 2017 | 2.69 Mn |
| Mar 31, 2017 | 3.37 Mn |
| Dec 31, 2016 | 4.83 Mn |
| Sep 30, 2016 | 3.62 Mn |
| Jun 30, 2016 | 4.31 Mn |
| Mar 31, 2016 | 4.22 Mn |
| Dec 30, 2015 | 3.21 Mn |
| Sep 30, 2015 | 2.60 Mn |
| Jun 30, 2015 | 2.35 Mn |
| Mar 31, 2015 | 2.55 Mn |